Royalty Pharma (FRA:RPD) Retained Earnings: €2,169 Mil (As of Mar. 2026)


FRA:RPD Royalty Pharma PLC FRA:RPD
70 GF Score
Price €48.51
GF Value €32.10
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Royalty Pharma Retained Earnings?

Royalty Pharma FRA:RPD -2.98% 70 Retained Earnings is €2,169 Mil as of Mar. 2026. GuruFocus rates FRA:RPD with a GF Score™ of 70/100 and a GF Value™ of €32.10 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Royalty Pharma's retained earnings for the quarter that ended in Mar. 2026 was €2,169 Mil.

Royalty Pharma's quarterly retained earnings increased from Sep. 2025 (€1,963 Mil) to Dec. 2025 (€2,012 Mil) and increased from Dec. 2025 (€2,012 Mil) to Mar. 2026 (€2,169 Mil).

Royalty Pharma's annual retained earnings increased from Dec. 2023 (€2,309 Mil) to Dec. 2024 (€2,718 Mil) but then declined from Dec. 2024 (€2,718 Mil) to Dec. 2025 (€2,012 Mil).


Royalty Pharma  (FRA:RPD) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Royalty Pharma Retained Earnings Historical Data

* Premium members only.

The historical data trend for Royalty Pharma's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Royalty Pharma Retained Earnings Chart

Royalty Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only 1,995.83 1,854.67 2,308.62 2,717.60 2,012.30

Royalty Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,294.61 1,927.12 1,963.28 2,012.30 2,168.63
FRA:RPD
70GF Score
Royalty Pharma PLC FRA:RPD
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Royalty Pharma Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of €2,169 Mil mean?
Royalty Pharma (FRA:RPD) has a Retained Earnings of €2,169 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Royalty Pharma and its competitors.
Is Royalty Pharma's Retained Earnings too high?
Royalty Pharma's current Retained Earnings is €2,169 Mil. Overall, Royalty Pharma has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's Retained Earnings compare to ROIV and MRNA?
Royalty Pharma's Retained Earnings of €2,169 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Royalty Pharma and its competitors. Royalty Pharma's current Retained Earnings is €2,169 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Based on GuruFocus' analysis, Royalty Pharma (FRA:RPD) is currently considered Significantly Overvalued. The stock's GF Value™ is €32.10, compared to a current price of €48.51 — trading 51.1% above its estimated fair value. The current Retained Earnings is €2,169 Mil. Royalty Pharma's overall GF Score™ is 70/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Royalty Pharma (FRA:RPD), the current Retained Earnings is €2,169 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Royalty Pharma (FRA:RPD) Overvalued in 2026?

Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued. The current stock price of €48.51 is trading 51.1% above its estimated GF Value™ of €32.10. GuruFocus considers Royalty Pharma to be Significantly Overvalued.

Key valuation signals for FRA:RPD:

  • Retained Earnings: €2,169 Mil
  • GF Value™: €32.10 vs. price of €48.51 (51.1% above fair value)
  • GF Score™: 70/100 with 10 warning signs

No single metric tells the full story. See the FRA:RPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Royalty Pharma Business Description

Other Exchanges RPRX:USA
Address 110 East 59th Street, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
70GF Score

Get the complete analysis for FRA:RPD

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€48.51
Price
€32.10
GF Value